OR-RADISYS
11.10.2021 08:02:04 CEST | Business Wire | Press release
Radisys® Corporation , a global leader of open telecom solutions, today announced its Connect Open Broadband solution showcase in Booth A24 at Broadband World Forum 2021, with the event exhibition taking place October 13-14 in Amsterdam, and the online event occurring October 11-15. Radisys will present live demonstrations that enable broadband service providers to transform their networks, simplify network operations, and be prepared to meet their customers’ changing needs. Radisys will demonstrate triple-play services, including high-speed internet and video streaming over Gigabit-PON (G-PON) and XGS-PON, and its Smart Home portfolio —including the Radisys Reach Smart Home Gateway and customizable mobile application—along with a sampling of available sensors, cameras and other devices that work together as an integrated solution.
Radisys will join other industry thought leaders in sessions exploring broadband innovation:
- Rajesh Chundury, VP of Customers Solutions, will present, “Advance Your FTTx Network with Cloud-Native Containerized Solutions for PON” on October 11 at 10:30am in the virtual session and live in-person October 14 from 2:10pm-2:30pm.
- Chundury will also participate in the Open Networking Foundation’s workshop “Taking opensource to production in broadband network with VOLTHA, a community view” on October 13, 3:00pm-5:00pm. The discussion will also feature experts from Adtran, Deutsche Telekom, Netsia and Türk Telekom.
The Radisys showcase will feature key solutions from its broadband and Smart Home portfolios. The demonstrations will include the Connect Broadband Access Controller (CBAC)-C (Centralized) and CBAC-D (Distributed) deployments using Radisys’ RLT-1600G and RLT-1600X Optical Line Terminals (OLTs) for fiber to the x (FTTX) deployments.
- Radisys’ CBAC software enables service providers to evolve their fiber networks with an open software solution that facilitates faster product innovation cycles, increased automation, and deeper network visibility.
- The Radisys Combo PON OLT features full PON port flexibility and enables broadband providers to leverage G-PON technology while also providing the option to expand their network and rollout XGS-PON deployments using the same OLT hardware at their pace and optimizing their cost model.
- Radisys’ Optical Network Terminals (ONTs) are built with inherent efficiencies and scalability to support data, voice, video and other broadband services for residential and commercial subscribers on fiber networks.
- Radisys’ Smart Home solutions help service providers broaden the utility of their data plans with life-enriching services and features that consumers want, to create new revenue streams and increase average revenue per user.
“Radisys is delivering best-in-class devices and leading software solutions that add value to the broadband ecosystem, elevating broadband service provider offerings and enhancing their data plans,” said Harris Razak, senior vice president of Broadband Access, Radisys. “Broadband World Forum 2021 is an exciting opportunity to showcase our portfolio that enables service providers to expand their fiber networks with world class solutions and leverage an open device ecosystem to create new revenue streams.”
To see the technology demonstrations, or to meet with Radisys’ open telecom experts at Broadband World Forum 2021, contact open@radisys.com .
About Radisys
Radisys, a global leader in open telecom solutions, enables service providers to drive disruption with new open architecture business models. Radisys’ innovative disaggregated and virtualized enabling technology solutions leverage open reference architectures and standards, combined with open software and hardware to power business transformation for the telecom industry, while its world-class services organization delivers systems integration expertise necessary to solve communications and content providers’ complex deployment challenges. For more information, visit www.Radisys.com .
Radisys® is a registered trademark of Radisys. All other trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211010005025/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom